Financial Performance - Net profit attributable to shareholders was CNY 1,007,104.04, down 51.40% year-on-year[12]. - Operating income for the period was CNY 25,990,213.95, a decrease of 5.70% compared to the same period last year[12]. - The company's weighted average return on net assets attributable to shareholders was 0.43%, down from 0.78% in the previous year[10]. - Total operating revenue for Q1 2023 was ¥25,990,213.95, a decrease of 5.7% from ¥27,561,364.26 in Q1 2022[56]. - Net profit for Q1 2023 was ¥978,994.81, down 52.8% from ¥2,072,317.04 in Q1 2022[57]. - The company's operating profit for Q1 2023 was ¥995,316.30, compared to ¥2,232,202.96 in Q1 2022, reflecting a decrease of 55.5%[56]. - The total profit for Q1 2023 was ¥995,316.30, compared to ¥2,224,783.73 in Q1 2022, indicating a decrease of 55.4%[57]. - The company reported investment income of ¥152,837.78 in Q1 2023, down from ¥342,850.02 in Q1 2022, a decline of 55.5%[56]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 251,814,357.83, a decrease of 0.07% compared to the end of the previous year[10]. - The company's asset-liability ratio (consolidated) was 7.05%, down from 7.51% at the end of the previous year[10]. - Total liabilities decreased from CNY 18,927,763.76 to CNY 17,757,123.70, a decline of about 6.2%[50]. - Current liabilities decreased from CNY 18,844,125.25 to CNY 17,673,485.19, a reduction of approximately 6.2%[49]. - The total non-current assets increased to ¥146,311,978.53 from ¥125,815,982.62, showing an increase of approximately 16.3%[48]. - The company's debt investment increased significantly to ¥121,398,282.53 from ¥101,020,670.90, representing a growth of about 20.2%[48]. Cash Flow - Net cash flow from operating activities increased by 307.16% to CNY 2,737,745.79 due to increased product sales and improved collection efforts[14]. - Operating cash inflow for Q1 2023 reached ¥54,665,244.60, a significant increase from ¥29,758,286.00 in Q1 2022, representing an 83.6% growth[61]. - Net cash flow from operating activities for Q1 2023 was ¥2,737,745.79, compared to ¥672,398.83 in Q1 2022, indicating a substantial improvement[62]. - Cash outflow from investment activities in Q1 2023 totaled ¥27,377,925.67, up from ¥23,558,734.64 in Q1 2022, reflecting increased investment efforts[62]. - The net increase in cash and cash equivalents for Q1 2023 was -¥2,613,054.90, contrasting with an increase of ¥24,272,682.04 in Q1 2022, signaling a challenging financial environment[62]. Shareholder Information - The total number of ordinary shareholders was 4,773 at the end of the reporting period[17]. - Liu Jinping and Liu Pingxiang hold 33.2348% and 21.9104% of the shares respectively, together controlling 55.1452% of the voting rights of the company[21]. - The total number of shares held by the top ten shareholders is 122,434,054, accounting for 76.3888% of the total shares[21]. - The largest shareholder, Liu Jinping, has a total of 53,268,016 shares, which is 33.2348% of the total shares[18]. - The company has a total of 70,083,206 shares that are not subject to any restrictions[21]. Compliance and Commitments - The company has committed to avoiding related party transactions and has not engaged in any such transactions during the reporting period[31][35]. - The actual controller has provided a commitment to avoid any competition with the company, ensuring no direct or indirect involvement in similar business activities[29][30]. - The company has committed to strict compliance with regulations regarding social insurance and housing funds, with a plan to increase awareness among employees[33][34]. - The company has established a framework for new commitments in case of non-fulfillment, which will be subject to shareholder approval[43]. - The company will comply with all relevant regulations regarding share reduction and disclosure obligations[37]. Operational Efficiency - The company plans to focus on market expansion and new product development in the upcoming quarters[60]. - Cash inflow from other operating activities in Q1 2023 was ¥11,842,880.77, a significant rise from ¥422,665.75 in Q1 2022, indicating enhanced operational efficiency[61]. - Research and development expenses decreased to ¥706,165.48 in Q1 2023 from ¥885,122.06 in Q1 2022, a reduction of 20.2%[56].

Revenue Performance - The company's total revenue for the first nine months of 2023 was CNY 119.30 million, representing a 12.52% increase compared to CNY 106.03 million in the same period of 2022[4] - The company's revenue for Q3 2023 was CNY 37.26 million, a decrease of 10.86% from CNY 41.80 million in Q3 2022[5] - The company corrected its revenue figures for previous periods, with the revised revenue for the first nine months of 2023 now reported as CNY 72.83 million, a 4.51% increase from CNY 69.68 million in the same period of 2022[6] - Total operating revenue for the first nine months of 2023 reached ¥72,826,122.32, an increase from ¥69,680,718.72 in the same period of 2022, representing a growth of approximately 3.1%[9] Profitability - The net profit attributable to shareholders for the first nine months of 2023 was CNY 5.50 million, a decrease of 62.24% from CNY 14.58 million in the same period of 2022[4] - The net profit attributable to shareholders for Q3 2023 was CNY 2.42 million, down 71.32% from CNY 8.43 million in Q3 2022[5] - Net profit for the first nine months of 2023 was ¥5,414,346.00, down from ¥14,575,213.77 in 2022, indicating a decline of approximately 62.9%[10] - The profit attributable to the parent company's shareholders was ¥5,504,019.06, compared to ¥14,575,213.77 in the previous year, a decrease of around 62.2%[11] - Operating profit for the first nine months of 2023 was ¥5,825,842.70, a decrease from ¥10,912,437.66 in 2022, representing a decline of approximately 46.6%[10] - The company reported a comprehensive income total of ¥5,414,346.00 for 2023, down from ¥14,575,213.77 in 2022, indicating a decrease of about 62.9%[11] Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was CNY 8.63 million, down 76.35% from CNY 36.52 million in the same period of 2022[4] - The net cash flow from operating activities for Q3 2023 was CNY 6.64 million, a decrease of 30.20% from CNY 9.51 million in Q3 2022[5] Earnings Per Share - The basic earnings per share for the first nine months of 2023 was CNY 0.03, a decline of 62.47% compared to CNY 0.09 in the same period of 2022[4] - Basic and diluted earnings per share for 2023 were both ¥0.03, down from ¥0.09 in 2022, reflecting a decline of 66.7%[11] Operating Costs and Income - Total operating costs increased to ¥70,647,120.37 in 2023 from ¥63,995,115.27 in 2022, reflecting a rise of about 10.3%[10] - Other income increased to ¥300,210.70 in 2023 from ¥74,035.92 in 2022, showing a significant rise of about 305.0%[10] - Investment income rose to ¥4,257,151.85 in 2023, compared to ¥2,030,779.45 in 2022, marking an increase of approximately 109.0%[10] Future Outlook - The company plans to continue focusing on new product development and market expansion strategies to improve future performance[3] Apology for Corrections - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[12]

Financial Performance - The company's corrected operating revenue for 2021 is $135,985,501.23, reflecting a year-over-year increase of 6.78% compared to 2020[4]. - The net profit attributable to shareholders for 2021 is $40,017,018.30, showing a slight decrease of 0.17% from the previous year[5]. - The gross profit margin for 2021 is reported at 43.98%, down from 49.75% in 2020[5]. - The basic earnings per share (EPS) for 2021 is $0.25, representing a decrease of 35.90% compared to $0.39 in 2020[5]. - The net cash flow from operating activities for 2021 is $25,658,464.35, an increase of 5.34% from 2020[6]. - The total asset growth rate for 2021 is 30.12%, compared to 16.04% in 2020[7]. - The company reported a discrepancy in the audited operating revenue of $135,985,501.23, which is a 1.03% difference from the preliminary report[9]. - The quarterly operating revenue for Q3 2021 was corrected to $37,812,158.35, down from the previously reported figure[12]. - The net profit attributable to shareholders for Q1 2021 was $8,884,754.91, with no changes reported in subsequent quarters[12]. Revenue and Costs - Operating costs rose to 76,174.68 million yuan, reflecting a growth of 19.04% year-on-year[15]. - The operating cost for the reporting period was 76,174,676.13 CNY, which represents a 19.04% increase year-on-year[25]. - The total operating costs for 2021 amounted to CNY 100,217,487.88, compared to CNY 84,267,436.86 in 2020, indicating an increase of about 18.9%[48]. Research and Development - Research and development expenses decreased by 15.40% to 3,983.70 million yuan, primarily due to reduced direct material costs[19]. - Research and development (R&D) expenses were CNY 3,983,697.54, accounting for 3.70% of operating revenue[44]. - The company confirmed that there were no capitalized R&D expenses during the reporting period[44]. Investment and Income - Investment income increased by 52.79% to 5,069.47 million yuan, attributed to higher net profits from associated companies[20]. - The company reported a significant increase in fair value gains of 1,293.87 million yuan, up 1255.72% year-on-year[20]. - The company reported a significant increase in government subsidies, leading to a 53.33% rise in non-operating income[29]. Customer and Supplier Concentration - The total sales amount from the top five customers was 59,909.68 million, accounting for 44.06% of total sales[36]. - The largest customer, Guangxi Liaoda Agricultural Technology Group, contributed 30,724.55 million, representing 22.59% of total sales[36]. - The total procurement amount from the top five suppliers was 38,663.35 million, accounting for 49.72% of total procurement[38]. - The largest supplier accounted for 28.84% of total procurement, amounting to 22,430.52 million[38]. Regional Performance - The company’s gross profit margin in the South China region was 32.84%, with a significant increase of 76.39% compared to the same period last year[34]. - The Northeast region reported a gross profit margin of 59.77%, a decrease of 6.86 percentage points compared to the previous year[34]. Apologies and Corrections - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[57].

Recognition and Awards - The company was recognized as a key agricultural leading enterprise in Guangdong Province for 2022[4] - The company has been acknowledged as a specialized and innovative small and medium-sized enterprise in Guangdong Province for 2022[4] - The company received the "Annual Efficiency and Cost Reduction Service Provider" award from China Agricultural and Animal Husbandry Wind and Cloud[4] - The product "Xie Xue Le (poultry use)" was awarded the title of high-tech product in Guangdong Province[4] Intellectual Property and R&D - The company added 4 new patent authorizations in 2023, enhancing its intellectual property portfolio[4] - The company continued to invest in R&D, obtaining 4 new patents and applying for 11 additional patents during the reporting period[49] - The number of patents held by the company increased from 17 to 19, including 7 invention patents[93] - The company has developed a high-efficiency mycotoxin degradation enzyme to address mycotoxin contamination in feed, which is expected to improve feed safety and animal health[95] - The company has successfully developed a product to improve the production performance of dairy cows suffering from postpartum paralysis, which is expected to enhance economic benefits in the ruminant market[96] - The company has developed a fermentation technology to control moisture in fermented soybean meal, enhancing the nutritional value of feed[95] Financial Performance - The company's operating revenue for 2023 was ¥93,474,624.44, a decrease of 3.71% compared to ¥97,072,539.68 in 2022[27] - The net profit attributable to shareholders for 2023 was ¥5,914,715.05, reflecting a significant decline of 66.01% from ¥17,400,190.18 in 2022[27] - The gross profit margin for 2023 was 27.11%, down from 30.56% in 2022[27] - Total assets at the end of 2023 amounted to ¥238,152,812.43, a decrease of 5.50% from ¥252,004,359.05 in 2022[29] - The total liabilities decreased by 53.24% to ¥8,857,962.65 in 2023 from ¥18,945,256.33 in 2022[29] - The net asset attributable to shareholders was ¥229,284,382.11 at the end of 2023, down 1.52% from ¥232,831,388.27 in 2022[29] - The basic earnings per share for 2023 was ¥0.04, a decrease of 63.64% from ¥0.11 in 2022[27] - The operating cash flow for 2023 was ¥10,444,302.81, representing an 80.83% decline from ¥54,469,487.07 in 2022[29] Revenue Adjustments and Reporting - The company reported a 33.25% difference in operating revenue between the preliminary report and the audited figures, with the latter confirming ¥93,474,624.44[30] - The company plans to correct prior financial statements due to revenue recognition adjustments, impacting reported revenues and costs for previous periods[30] - The company has identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue recognition timing[101] Market Challenges and Strategies - The feed industry faced challenges, with the company’s revenue declining by 3.71% due to pressures from raw material prices and market conditions[46] - The company is focused on expanding its product offerings in the ruminant and aquaculture sectors to leverage its core competencies[117] - The company plans to expand its product range to include markets for aquaculture and ruminants, aiming to mitigate the impact of major epidemics affecting specific animal types[127] - The company acknowledges the high costs and long cycles associated with research and development in the feed additive industry, which may lead to uncertainties in product development and market competitiveness[127] Corporate Governance and Compliance - The company has established measures for accountability among directors and executives in case of unfulfilled commitments, including potential salary reductions[149] - The company has established a decision-making system for related transactions to minimize and regulate such transactions[136] - The company has implemented a responsibility accountability system for major errors in the annual report[198] - The company has ensured compliance with relevant laws and regulations in its operations and information disclosure[199] Shareholder and Management Information - The company has committed to a profit distribution policy that aligns with relevant laws and regulations, ensuring compliance post-listing on the selected tier[150] - The total number of unrestricted shares decreased from 90,194,394 to 90,037,719, representing a change of -156,675 shares, which is a decrease of approximately 0.17%[155] - The controlling shareholders, Liu Jinping and Liu Pingxiang, hold 53,476,916 shares (33.37%) and 35,117,429 shares (21.91%) respectively, indicating significant ownership concentration[156] - The company has not made any changes to its controlling shareholder or actual controller during the reporting period[164] Employee and Management Changes - The company experienced a net decrease of 2 employees, ending the period with a total of 79 employees[187] - The financial director position changed due to retirement, with a new hire, Shen Jia, taking over[181] - The company has implemented a performance-based salary system for employees, encouraging higher productivity[188] - The company has a training plan that includes internal and external training to enhance management and sales capabilities[189] Future Plans and Commitments - The company plans to enhance its product offerings through the development of a new blood-boosting feed additive aimed at improving poultry health[94] - The company intends to optimize and upgrade its hematopoietic products continuously, addressing anemia issues in intensive farming[120] - The company is committed to fulfilling its social responsibilities by adhering to tax regulations and providing employment opportunities to local residents[112]

Financial Performance - Operating revenue for Q1 2024 was CNY 16,393,329.34, representing a significant decrease of 36.92% from CNY 25,990,213.95 in Q1 2023[11] - Net profit attributable to shareholders for Q1 2024 reached CNY 3,125,043.31, a remarkable increase of 210.30% compared to CNY 1,007,104.04 in the same period last year[11] - The company reported a basic earnings per share of CNY 0.02 for Q1 2024, up from CNY 0.01 in Q1 2023, reflecting improved profitability[11] - Total operating revenue for Q1 2024 was CNY 16,393,329.34, a decrease from CNY 25,990,213.95 in Q1 2023[36] - Net profit for Q1 2024 reached CNY 3,125,576.46, compared to CNY 978,994.81 in Q1 2023, representing a significant increase[37] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.02, an increase from CNY 0.01 in Q1 2023[38] - Total comprehensive income for Q1 2024 was ¥2,780,073.07, compared to ¥1,612,638.75 in Q1 2023, reflecting an increase of approximately 72.2%[40] Assets and Liabilities - Total assets as of March 31, 2024, amounted to CNY 239,249,926.97, reflecting a 0.46% increase compared to CNY 238,152,812.43 at the end of 2023[11] - The asset-liability ratio for the consolidated entity decreased to 2.80% from 3.72% year-over-year, indicating improved financial stability[11] - Total current assets decreased to ¥31,189,464.54 from ¥31,626,858.59, a decline of approximately 1.4%[30] - Total current liabilities decreased to ¥5,845,939.89 from ¥8,122,078.35, a decline of about 28.0%[32] - Total liabilities decreased to ¥6,704,733.40 from ¥8,857,962.65, a reduction of approximately 24.3%[32] - The company reported a total equity of ¥232,545,193.57, up from ¥229,294,849.78, indicating a growth of about 1.0%[32] Research and Development - Research and development expenses increased by 59.07% to CNY 1,123,287.56 in Q1 2024, indicating a focus on enhancing R&D efforts[13] - Research and development expenses for Q1 2024 were CNY 1,123,287.56, up from CNY 706,165.48 in Q1 2023, indicating a focus on innovation[36] - Research and development expenses rose to ¥1,027,372.94 in Q1 2024, up from ¥616,381.60 in Q1 2023, indicating a growth of approximately 66.7%[39] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY -1,657,056.80, a decline of 160.53% compared to the previous year[13] - The net cash flow from operating activities for Q1 2024 was -¥1,657,056.80, a decline from ¥2,737,745.79 in Q1 2023[41] - Cash and cash equivalents at the end of Q1 2024 were ¥7,571,668.59, down from ¥13,068,088.64 at the end of Q1 2023[42] - Operating cash inflow for Q1 2024 totaled ¥13,705,227.12, down from ¥24,138,682.07 in Q1 2023[43] Shareholder Information - The total number of shares outstanding is 160,277,600, with 56.18% being unrestricted shares[20] - Major shareholders include Liu Jinping and Liu Pingxiang, holding 33.36% and 21.91% of shares respectively, totaling 55.27% combined[22] - The company has 4,124 common shareholders as of the end of the reporting period[20] - The total number of restricted shares is 70,239,881, representing 43.82% of total shares[20] - Liu Jinping and Liu Pingxiang also hold indirect stakes through various partnerships, controlling a total of 57.6457% of the company[22] Legal Matters - The company is involved in a lawsuit regarding a contract dispute, with a claim for 4,400,000.00 yuan and interest of 220,522.50 yuan[26] - The company has frozen assets amounting to 4,620,522.5 yuan as part of the legal proceedings[26] - There are no pledged or judicially frozen shares among the major shareholders[23] - The company has not issued any preferred shares during the reporting period[23] - The company has not disclosed any significant related party transactions during the reporting period[25] Inventory and Receivables - Accounts receivable slightly decreased to ¥12,916,935.96 from ¥13,086,445.06, a reduction of about 1.3%[30] - Inventory increased significantly to ¥6,848,998.41 from ¥5,286,351.67, representing a growth of approximately 29.5%[30]

北京市中伦（广州）律师事务所 关于广东驱动力生物科技集团股份有限公司 2022 年股权激励计划 注销部分已获授但尚未行权的股票期权的 法律意见书 二〇二四年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 中伦是一家特殊的普通合伙制律师事务所 Zhong Lun is formed as an LLP under PRC law. 广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/ ...

审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-79 | 广东驱动力生物科技集团股份有限公司 审计报告 大华审字[2024]0011001141 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 广东驱动力生物科技集团股份有限公司 大华会计师事务所（特殊普通合伙） 北京市海淀区 ...

广东驱动力生物科技集团股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字【2024】0011002889 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 广东驱动力生物科技集团股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 广东驱动力生物科技集团股份有限公司 2023 年度非经营性资金占用及其他关联资金往来 情况汇总表 1 资 金 占 用 情 况 的 专 项 说 明 大华核字【2024】0011002889 号 广东驱动力生物科技集团股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业准则》审计了广东驱 动力生物科技集团股份有限公司（以下简称驱动力公司）2023 年度 财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表和合 ...

广东驱动力生物科技集团股份有限公司 前期重大会计差错更正专项说明的鉴证报告 大华核字【2024】0011011593 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 广东驱动力生物科技集团股份有限公司 前期重大会计差错更正专项说明的鉴证报告 （截止 2023 年 12 月 31 日） 一. 前期重大会计差错更正专项说明的鉴证报告 1-2 二. 广东驱动力生物科技集团股份有限公司前期 重大会计差错更正专项说明 1-3 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 前 期 重 大 差 错 更 正 专 项 说 明 的 鉴 证 报 告 大华核字【2024】0011011593 号 广东驱动力生物科技集团股份有限公司全体股东： 我们接受委托，审核了后附的广东驱动力生物科技集团股份有限 公司（以下简 ...

2023 年度独立董事述职报告（习欠云-已离任） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人习欠云为广东驱动力生物科技集团股份有限公司(以下简称"公司") 的 第三届董事会独立董事，因连续担任公司独立董事已满 6 年，自 2023 年 11 月 16 日起不再担任公司独立董事及各专门委员会委员职务。本人在任职期间严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交易所股票 上市规则（试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董 事》、等法律法规的规定以及《公司章程》和《独立董事工作制度》的要求，谨 慎、认真、勤勉、独立地履行职责，持续关注公司规范运作、重大生产经营活动、 财务状况等，积极出席 2023 年度的相关会议，认真审议各项议案，对重大事项 发表了独立意见，维护了公司整体利益和全体股东尤其是中小股东的合法权益。 现就 2023 年度任职期间内履行职责情况汇报如下： 证券代码：838275 证券简称：驱动力 公告编号：2024-028 广东驱动力生物科 ...